- Home
- DTE vs ILMN Comparison
DTE vs ILMN Comparison
Compare DTE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTE
- ILMN
- Stock Information
- Founded
- DTE 1903
- ILMN 1998
- Country
- DTE United States
- ILMN United States
- Employees
- DTE N/A
- ILMN N/A
- Industry
- DTE Electric Utilities: Central
- ILMN Medical Specialities
- Sector
- DTE Utilities
- ILMN Health Care
- Exchange
- DTE Nasdaq
- ILMN Nasdaq
- Market Cap
- DTE 26.1B
- ILMN 23.6B
- IPO Year
- DTE N/A
- ILMN 2000
- Fundamental
- Price
- DTE $121.00
- ILMN $147.64
- Analyst Decision
- DTE Buy
- ILMN Buy
- Analyst Count
- DTE 16
- ILMN 19
- Target Price
- DTE $130.62
- ILMN $162.67
- AVG Volume (30 Days)
- DTE 1.5M
- ILMN 2.1M
- Earning Date
- DTE 02-06-2025
- ILMN 02-06-2025
- Dividend Yield
- DTE 3.60%
- ILMN N/A
- EPS Growth
- DTE 21.85
- ILMN N/A
- EPS
- DTE 7.38
- ILMN N/A
- Revenue
- DTE $12,415,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- DTE $1.31
- ILMN N/A
- Revenue Next Year
- DTE $2.12
- ILMN $4.28
- P/E Ratio
- DTE $16.40
- ILMN N/A
- Revenue Growth
- DTE N/A
- ILMN N/A
- 52 Week Low
- DTE $102.17
- ILMN $97.36
- 52 Week High
- DTE $131.67
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- DTE 41.45
- ILMN 56.37
- Support Level
- DTE $119.52
- ILMN $138.88
- Resistance Level
- DTE $127.53
- ILMN $151.75
- Average True Range (ATR)
- DTE 1.60
- ILMN 4.96
- MACD
- DTE -0.17
- ILMN 0.76
- Stochastic Oscillator
- DTE 18.48
- ILMN 81.01
About DTE DTE Energy Company
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.